Wednesday, October 25, 2017
Amerigen Pharmaceuticals Limited and Biophore India Pharmaceuticals Pvt Ltd. announced that they are collaborating to bring a generic version of Valeant's Cuprimine and other penicillamine based generic products to the U.S. market using active pharmaceutical ingredient supplied by Biophore from India. Amerigen has already filed an Abbreviated New Drug Application ("ANDA") with the U.S Food & Drug Administration ("FDA") for potentially the first generic equivalent of Cuprimine, which has been accepted for filing and is now under FDA review. John Lowry, Amerigen's President & CEO, stated that "After the well publicized price increases for Cuprimine over the last several years, Amerigen looks forward to securing FDA approval for its pending ANDA and bringing a lower cost version of this important medication to U.S. patients."
